Aducanumab Terminated Phase 1 Trials for Alzheimer's Disease (AD) Treatment

IndicationsStatusPurposePhase
TerminatedTreatment1
clinicaltrials.gov IdentifierTitleDrugs
NCT01677572Multiple Dose Study of Aducanumab (BIIB037) (Recombinant, Fully Human Anti-Aβ IgG1 mAb) in Participants With Prodromal or Mild Alzheimer's Disease